VANDA PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VANDA PHARMACEUTICALS INC. (VNDA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.11M, a 0.05% increase year-over-year.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.56M, a 13.73% decline year-over-year.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.11M, a 29.58% decline year-over-year.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.11M, a 29.47% decline year-over-year.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.47M, a 23.79% decline from fiscal 2024.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.43M, a 11.45% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $14.04M, a 13.75% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.28M, a 5.89% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.11M 10-Q · filed 2026-08-06 | $4.67M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.56M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $9.47M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $2.11M 10-Q · filed 2025-10-30 | $4.22M derived: sum of 2 quarters · filed 2026-08-06 | $7.19M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $2.11M 10-Q · filed 2026-08-06 | $5.08M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $2.97M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $12.43M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $3.00M 10-Q · filed 2025-10-30 | $5.99M derived: sum of 2 quarters · filed 2025-10-30 | $9.57M derived: sum of 3 quarters · filed 2025-10-30 | ||
| 2024-06-30 | $2.99M 10-Q · filed 2025-10-30 | $6.57M derived: sum of 2 quarters · filed 2025-10-30 | |||
| 2024-03-31 | $3.58M 10-Q · filed 2025-10-30 | ||||
| 2023-12-31 | $14.04M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $3.17M 10-Q · filed 2024-11-07 | $6.42M derived: sum of 2 quarters · filed 2024-11-07 | $10.77M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $3.25M 10-Q · filed 2024-11-07 | $7.60M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $4.35M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $16.28M 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $3.89M 10-Q · filed 2023-11-09 | $7.72M derived: sum of 2 quarters · filed 2023-11-09 | $12.50M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $3.83M 10-Q · filed 2023-11-09 | $8.61M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $4.78M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $15.37M 10-K · filed 2024-02-08 | ||||
| 2021-09-30 | $3.95M 10-Q · filed 2022-11-03 | $7.69M derived: sum of 2 quarters · filed 2022-11-03 | $11.60M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $3.74M 10-Q · filed 2022-11-03 | $7.65M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $3.91M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $13.36M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $3.13M 10-Q · filed 2021-11-04 | $6.20M derived: sum of 2 quarters · filed 2021-11-04 | $10.15M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $3.07M 10-Q · filed 2021-11-04 | $7.01M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $3.94M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $13.46M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $3.41M 10-Q · filed 2020-10-29 | $6.51M derived: sum of 2 quarters · filed 2020-10-29 | $9.79M derived: sum of 3 quarters · filed 2020-10-29 | $12.71M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $3.10M 10-Q · filed 2020-10-29 | $6.38M derived: sum of 2 quarters · filed 2020-10-29 | $9.30M derived: sum of 3 quarters · filed 2021-02-11 | $12.18M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $3.28M 10-Q · filed 2020-10-29 | $6.20M derived: sum of 2 quarters · filed 2021-02-11 | $9.08M derived: sum of 3 quarters · filed 2021-02-11 | $11.80M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $5.79M derived: sum of 2 quarters · filed 2021-02-11 | $8.52M derived: sum of 3 quarters · filed 2021-02-11 | $11.67M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $2.87M 10-Q · filed 2019-11-07 | $5.59M derived: sum of 2 quarters · filed 2019-11-07 | $8.74M 10-Q · filed 2018-11-07 | $11.53M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | $2.72M 10-Q · filed 2019-11-07 | $5.87M 10-Q · filed 2018-08-02 | $8.65M derived: sum of 3 quarters · filed 2020-02-26 | $11.43M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | $3.15M 10-Q · filed 2019-11-07 | $5.93M derived: sum of 2 quarters · filed 2020-02-26 | $8.70M derived: sum of 3 quarters · filed 2020-02-26 | $11.36M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.55M derived: sum of 2 quarters · filed 2020-02-26 | $8.21M derived: sum of 3 quarters · filed 2020-02-26 | $10.46M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.43M derived: sum of 2 quarters · filed 2017-11-08 | $7.68M 10-Q · filed 2017-11-08 | $9.79M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $4.91M 10-Q · filed 2017-08-03 | $7.01M derived: sum of 3 quarters · filed 2019-02-19 | $9.12M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-03-31 | $2.26M 10-Q · filed 2017-05-03 | $4.36M derived: sum of 2 quarters · filed 2019-02-19 | $6.46M derived: sum of 3 quarters · filed 2019-02-19 | $8.53M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2016-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $4.20M derived: sum of 2 quarters · filed 2019-02-19 | $6.28M derived: sum of 3 quarters · filed 2019-02-19 | $8.54M 10-K · filed 2019-02-19 | |
| 2016-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $4.17M derived: sum of 2 quarters · filed 2016-11-03 | $6.44M 10-Q · filed 2016-11-03 | $8.33M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $4.34M 10-Q · filed 2016-07-28 | $6.23M derived: sum of 3 quarters · filed 2018-02-15 | $8.29M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-03-31 | $2.27M 10-Q · filed 2016-05-05 | $4.15M derived: sum of 2 quarters · filed 2018-02-15 | $6.21M derived: sum of 3 quarters · filed 2018-02-15 | $8.28M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2015-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $3.95M derived: sum of 2 quarters · filed 2018-02-15 | $6.02M derived: sum of 3 quarters · filed 2018-02-15 | $7.96M 10-K · filed 2018-02-15 | |
| 2015-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $4.13M derived: sum of 2 quarters · filed 2015-11-04 | $6.07M 10-Q · filed 2015-11-04 | $7.71M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $4.01M 10-Q · filed 2015-07-31 | $5.64M derived: sum of 3 quarters · filed 2017-02-17 | $7.05M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $1.95M 10-Q · filed 2015-05-07 | $3.58M derived: sum of 2 quarters · filed 2017-02-17 | $4.99M derived: sum of 3 quarters · filed 2017-02-17 | $6.43M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.04M derived: sum of 2 quarters · filed 2017-02-17 | $4.49M derived: sum of 3 quarters · filed 2017-02-17 | $5.88M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $2.85M derived: sum of 2 quarters · filed 2014-10-27 | $4.25M 10-Q · filed 2014-10-27 | $6.33M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $2.84M 10-Q · filed 2014-08-08 | $4.92M derived: sum of 3 quarters · filed 2016-02-12 | $6.46M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-03-31 | $1.39M 10-Q · filed 2014-05-08 | $3.48M derived: sum of 2 quarters · filed 2016-02-12 | $5.01M derived: sum of 3 quarters · filed 2016-02-12 | $5.84M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2013-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $3.62M derived: sum of 2 quarters · filed 2016-02-12 | $4.45M derived: sum of 3 quarters · filed 2016-02-12 | $5.40M 10-K · filed 2016-02-12 | $4.60M 10-K · filed 2014-02-25 |
| 2013-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $2.37M derived: sum of 2 quarters · filed 2013-11-08 | $3.32M 10-Q · filed 2013-11-08 | ||
| 2013-06-30 | $830.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $1.78M 10-Q · filed 2013-07-31 | |||
| 2013-03-31 | $952.00K 10-Q · filed 2013-05-10 | ||||
| 2012-12-31 | $5.05M 10-K · filed 2015-03-13 | $4.09M 10-K · filed 2013-02-26 | |||
| 2011-12-31 | $5.50M 10-K · filed 2014-02-25 | ||||
| 2010-12-31 | $4.98M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |